These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 3414319

  • 1. Primary treatment of macroprolactinomas with Parlodel LAR.
    van 't Verlaat JW, Lancranjan I, Hendriks MJ, Croughs RJ.
    Acta Endocrinol (Copenh); 1988 Sep; 119(1):51-5. PubMed ID: 3414319
    [Abstract] [Full Text] [Related]

  • 2. Bromocriptine treatment of prolactin secreting macroadenomas: a radiological, ophthalmological and endocrinological study.
    van 't Verlaat JW, Croughs RJ, Hendriks MJ, Bosma NJ, Nortier JW, Thijssen JH.
    Acta Endocrinol (Copenh); 1986 Aug; 112(4):487-93. PubMed ID: 3751462
    [Abstract] [Full Text] [Related]

  • 3. Treatment with long acting repeatable bromocriptine (Parlodel-LAR*) in patients with macroprolactinomas: long-term study in 29 patients.
    Jamrozik SI, Bennet AP, James-Deidier A, Tremollieres F, Saint-Martin F, Dumoulin S, Valat-Coustols M, de Glisezinski I, Tremoulet M, Manelfe C, Louvet JP.
    J Endocrinol Invest; 1996 Aug; 19(7):472-9. PubMed ID: 8884542
    [Abstract] [Full Text] [Related]

  • 4. Long-term treatment with a new repeatable injectable form of bromocriptine, Parlodel LAR, in patients with tumorous hyperprolactinemia.
    Ciccarelli E, Miola C, Avataneo T, Camanni F, Besser GM, Grossman A.
    Fertil Steril; 1989 Dec; 52(6):930-5. PubMed ID: 2591571
    [Abstract] [Full Text] [Related]

  • 5. Treatment of macroprolactinomas with the long-acting and repeatable form of bromocriptine: a report on 29 cases.
    Beckers A, Petrossians P, Abs R, Flandroy P, Stadnik T, de Longueville M, Lancranjan I, Stevenaert A.
    J Clin Endocrinol Metab; 1992 Jul; 75(1):275-80. PubMed ID: 1619019
    [Abstract] [Full Text] [Related]

  • 6. Long-acting injectable bromocriptine (Parlodel LAR) in the chronic treatment of prolactin-secreting macroadenomas.
    Lengyel AM, Mussio W, Imamura P, Vieira JG, Lancranjan I.
    Fertil Steril; 1993 May; 59(5):980-7. PubMed ID: 8486199
    [Abstract] [Full Text] [Related]

  • 7. Effectiveness of a long-acting injectable form of bromocriptine in patients with prolactin and growth hormone secreting macroadenomas.
    Tsagarakis S, Tsiganou E, Tzavara I, Nikolou H, Thalassinos N.
    Clin Endocrinol (Oxf); 1995 Jun; 42(6):593-9. PubMed ID: 7634499
    [Abstract] [Full Text] [Related]

  • 8. New long-acting bromocriptine (Parlodel MR and Parlodel LAR) in the treatment of pituitary tumours with hyperprolactinemia.
    Zgliczyński W, Zgliczyński S, Makowska A, Słowinska-Srzednicka J, Janik J, Jeske W, Walecki J.
    Endokrynol Pol; 1992 Jun; 43(3):234-41. PubMed ID: 1345564
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Results of primary treatment with bromocriptine of prolactinomas with extrasellar extension.
    van 't Verlaat JW, Croughs RJ, Hendriks MJ, Bosma NJ.
    Can J Neurol Sci; 1990 Feb; 17(1):71-3. PubMed ID: 2311021
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Chronic treatment with parlodel LAR of patients with prolactin-secreting tumours. Different responsiveness of micro- and macroprolactinomas.
    Maraschini C, Moro M, Masala A, Toja P, Alagna S, Brunani A, Rovasio PP, Ginanni A, Lancranjan I, Cavagnini F.
    Acta Endocrinol (Copenh); 1991 Nov; 125(5):494-501. PubMed ID: 1759539
    [Abstract] [Full Text] [Related]

  • 14. Parlodel LAR in the treatment of macroprolactinomas.
    Kocijancic A, Prezelj J, Vrhovec I, Lancranjan I.
    Acta Endocrinol (Copenh); 1990 Feb; 122(2):272-6. PubMed ID: 2316314
    [Abstract] [Full Text] [Related]

  • 15. Oral and injectable long-lasting bromocriptine preparations in hyperprolactinemia: comparison of their prolactin lowering activity, tolerability and safety.
    Merola B, Colao A, Caruso E, Sarnacchiaro F, Briganti F, Lancranjan I, Lombardi G, Schettini G.
    Gynecol Endocrinol; 1991 Dec; 5(4):267-76. PubMed ID: 1796748
    [Abstract] [Full Text] [Related]

  • 16. Acute effects of Parlodel-LAR and response to long-term treatment with bromocriptine in a patient with a follicle stimulating hormone-secreting pituitary adenoma.
    Abs R, Parizel PM, Beckers A.
    J Endocrinol Invest; 1991 Feb; 14(2):135-8. PubMed ID: 1905737
    [Abstract] [Full Text] [Related]

  • 17. Long-lasting suppression of prolactin secretion and rapid shrinkage of prolactinomas after a long-acting, injectable form of bromocriptine.
    Montini M, Pagani G, Gianola D, Pagani MD, Salmoiraghi M, Ferrari L, Lancranjan I.
    J Clin Endocrinol Metab; 1986 Jul; 63(1):266-8. PubMed ID: 3711262
    [Abstract] [Full Text] [Related]

  • 18. Long-acting injectable bromocriptine treatment for macroprolactinomas.
    Van Cutsem EJ, Lamberts SW.
    Neth J Med; 1988 Apr; 32(3-4):112-7. PubMed ID: 3362265
    [No Abstract] [Full Text] [Related]

  • 19. Mixed pituitary tumours--effects of bromocriptine treatment: Parlodel MR and Parlodel LAR.
    Zgliczyński W, Zgliczyński S, Makowska A, Słowinska-Srzednicka J, Janik J, Jeske W, Walecki J.
    Endokrynol Pol; 1992 Apr; 43(3):242-9. PubMed ID: 1345565
    [Abstract] [Full Text] [Related]

  • 20. Treatment of macroprolactinomas with a new non-ergot, long-acting dopaminergic drug, CV 205-502.
    van't Verlaat JW, Croughs RJ, Brownell J.
    Clin Endocrinol (Oxf); 1990 Nov; 33(5):619-24. PubMed ID: 1979262
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.